Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: MA NONMETROPOLITAN AREA — September 2026
Nonmetro Massachusetts talent gap widens as CRA pay diverges from national trend.
CRA advertised pay fell to a $58,922 metro median while the national median climbed to $90,956, as statewide unemployment eased to 4.3% and nonmetro talent pools kept shrinking.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Massachusetts unemployment rate: 4.3% — Lowest since March 2025; national rate 4.1%
- CRA advertised pay gap: $58,922 vs $90,956 — Metro down moderately vs national up significantly
- Massachusetts R&D job losses, 2025: -2,563 — Steepest decline among major U.S. R&D hubs
- MA biomanufacturing employment: 10,311 — vs 41,902 in California
Key takeaways
Nonmetro talent scarcity is structural, not seasonal.
Statewide R&D employment fell 2,563 jobs in 2025, the steepest drop among major U.S. hubs, while nonmetro areas lack the density to absorb that loss through local redeployment. Expect continued pressure on specialized scientist and regulatory retention outside the Boston-Cambridge corridor.
Clinical Research Associate pay is diverging sharply from the national trend.
Metro median advertised pay for CRAs sits at $58,922, down moderately, against a national median of $90,956 that's risen significantly. Nonmetro employers competing against Boston and national remote postings risk losing CRA talent unless pay bands are recalibrated against the national trajectory, not local history.
Lab Technician wages are softening in both directions.
Metro median pay of $52,500 is down moderately even as the national median also declined, suggesting broad softening in entry-level bench roles rather than a local anomaly. This may create near-term hiring opportunity for quality and manufacturing support roles that typically compete for the same talent pool.
Manufacturing capacity gaps keep outsourcing on the table.
Massachusetts biomanufacturing employment sits at 10,311 versus California's 41,902, even after adding 238 jobs in 2025. Nonmetro operations facing local hiring constraints may find CDMO capacity a faster route to scale than building internal manufacturing headcount.
Median advertised pay by role — MA NONMETROPOLITAN AREA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $113,536 | $142,638 | $153,000 | Significant increase | $131,354 |
| Clinical Research Associate | $51,136 | $58,922 | $60,340 | Moderate decline | $90,956 |
| Lab Technician * | $43,544 | $52,500 | $57,433 | Moderate decline | $47,402 |
| Regulatory Affairs Specialist * | $84,083 | $117,616 | $129,350 | Moderate decline | $104,000 |
| Clinical Data Manager * | $100,353 | $123,031 | $145,187 | Moderate decline | $123,031 |
| Biostatistician * | $107,561 | $147,083 | $165,000 | Moderate increase | $133,322 |
| Validation Engineer * | $95,510 | $114,868 | $124,869 | Moderate increase | $108,377 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Massachusetts nonmetropolitan labor markets remain structurally tight even as statewide unemployment eased to 4.3% in August, the lowest since March 2025, with all twelve state labor market areas posting declines month over month. Rural and small-city talent pools outside Boston-Cambridge continue shrinking as aging demographics and domestic outmigration restrain labor force growth, compounding the recruiting disadvantage these areas already face against the dense Boston life sciences cluster.
What it means
Thin local candidate pools outside the core Boston-Cambridge corridor push Life Sci employers in nonmetro Massachusetts toward wider geographic searches and remote/hybrid structures for regulatory, quality, and clinical roles that don't require bench presence, while manufacturing and CMC positions requiring on-site work face sharper scarcity premiums. Massachusetts' 2,563 R&D job losses in 2025 and continued underinvestment in biomanufacturing capacity relative to California intensify build-versus-outsource tradeoffs for nonmetro operations weighing CDMO partnerships against costly local hiring. Organizations should evaluate whether nonmetro-based manufacturing and quality roles can be competitively filled locally or whether CDMO capacity in denser hubs offers a faster, lower-risk path to scale.
Looking ahead
Expected release: September local unemployment data for Massachusetts labor market areas publishes October 20, 2026, offering the first nonmetro-specific read on whether August's statewide improvement held at the regional level.
Worth watching: Sanofi's 385 new hires in 2026 signal selective post-consolidation expansion; watch whether this hiring extends beyond Boston-Cambridge into nonmetro sites or stays concentrated in the core cluster.
Emerging pressure point: Healthcare accounted for 20 of 72 statewide WARN notices in 2026, with the largest single filing (639 jobs, Community Healthlink) in Worcester/Leominster. Watch whether displaced clinical and lab talent migrates into nonmetro Life Sci openings.
Potential inflection point: Biopharma hiring nationally remains selective despite layoffs, with 64% of surveyed organizations still actively recruiting. Nonmetro Massachusetts employers should watch whether this national selectivity translates into renewed competition for scarce regulatory and CMC talent locally.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.